...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical and applied thrombosis/hemostasis : >Retrospective Review of Prescribing Patterns in Cancer-Associated Thrombosis: A Single Center Experience in Edmonton, Alberta, Canada
【24h】

Retrospective Review of Prescribing Patterns in Cancer-Associated Thrombosis: A Single Center Experience in Edmonton, Alberta, Canada

机译：癌症相关血栓形成规定模式的回顾述评：加拿大艾伯塔省埃德蒙顿的单一中心经验

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Low molecular weight heparin (LMWH) is the standard of care for treating cancer-associated thrombosis (CAT), although new evidence for direct oral anticoagulants (DOACs) supports use in specific cancer populations. In this retrospective review at a specialty CAT clinic from 2016 to 2019, we report the use of anticoagulants (LMWH, DOACs, warfarin, anticoagulant class change) in the acute and chronic phases of CAT and compare use before/after publication of the Hokusai-VTE Cancer trial. Death, venous thromboembolism (VTE) recurrence and bleeding was also reported. Of the 221 included, median age was 69 years, with 57.5% having metastatic disease. In the acute phase, 80.1% were prescribed LMWH, 4.1% DOAC, and 14.5% had an anticoagulant class change (LMWH to DOAC; 78.1%). In the chronic phase, 35.8% were prescribed LMWH, 11.3% DOAC, and 42.9% had an anticoagulant class change (LMWH to DOAC; 90.1%). Use of DOACs in the acute and chronic phase prior to the Hokusai-VTE trial was 1.0% and 2.0%, respectively, and following publication was 6.8% and 19.6%. Death occurred for 22.6% patients, recurrent VTE in 7.2%, and bleeding in 5.0%. DOAC use is increasing with time; real-world data may help to guide optimization of the care of complex patients.
机译：低分子量肝素（LMWH）是治疗癌症相关血栓形成（猫）的护理标准，尽管用于直接口服抗凝血剂（DOACS）的新证据支持特异性癌症群体。在2016年至2019年特色猫诊所的这一回顾审查中，我们举报使用抗凝血剂（LMWH，DoAC，Warfarin，抗凝血类，抗凝血剂阶级变化）在猫的急性和慢性阶段，并在Hokusai出版之前/之后进行比较VTE癌症试验。还报道了死亡，静脉血栓栓塞（VTE）复发和出血。其中221个中位年龄为69岁，具有57.5％具有转移性疾病。在急性期，80.1％规定的LMWH，4.1％DOAC，14.5％具有抗凝血类变化（LMWH到DOAC; 78.1％）。在慢性阶段，35.8％规定了LMWH，11.3％DOAC，42.9％具有抗凝血类变化（LMWH到DOAC; 90.1％）。在Hokusai-VTE试验之前的急性和慢性阶段使用DoAC，分别为1.0％和2.0％，后续出版物为6.8％和19.6％。 22.6％患者发生死亡，复发性VTE为7.2％，血液出血5.0％。 Doac使用随着时间的推移而增加;现实世界的数据可能有助于指导优化复杂患者的护理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号